NEW YORK, May 21 (Reuters) - Bristol-Myers Squibb Co.'s schizophrenia drug Abilify proved effective as an add-on therapy for patients suffering from major depression who were not getting satisfactory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback